269.38
1.33%
-3.63
After Hours:
267.60
-1.78
-0.66%
AMGEN Inc. stock is currently priced at $269.38, with a 24-hour trading volume of 1.74M.
It has seen a -1.33% decreased in the last 24 hours and a -4.07% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $272.5 pivot point. If it approaches the $267.3 support level, significant changes may occur.
Previous Close:
$273.01
Open:
$273.45
24h Volume:
1.74M
Market Cap:
$144.49B
Revenue:
$28.19B
Net Income/Loss:
$6.72B
P/E Ratio:
19.15
EPS:
14.07
Net Cash Flow:
$7.36B
1W Performance:
+2.52%
1M Performance:
-4.07%
6M Performance:
-1.02%
1Y Performance:
+10.01%
AMGEN Inc. Stock (AMGN) Company Profile
Name
AMGEN Inc.
Sector
Industry
Phone
805-447-1000
Address
One Amgen Center Drive, Thousand Oaks, CA
AMGEN Inc. Stock (AMGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-28-24 | Resumed | Raymond James | Mkt Perform |
Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Nov-02-23 | Upgrade | Truist | Hold → Buy |
Oct-20-23 | Resumed | JP Morgan | Neutral |
Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
Oct-11-23 | Resumed | BofA Securities | Neutral |
Sep-06-23 | Initiated | HSBC Securities | Buy |
Apr-24-23 | Reiterated | Oppenheimer | Outperform |
Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Feb-13-23 | Reiterated | Truist | Buy |
Nov-18-22 | Initiated | Credit Suisse | Underperform |
Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
Feb-09-22 | Reiterated | Barclays | Equal Weight |
Feb-09-22 | Reiterated | Jefferies | Buy |
Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
Feb-09-22 | Reiterated | Oppenheimer | Outperform |
Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
Dec-06-21 | Initiated | Goldman | Buy |
Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-29-20 | Initiated | Daiwa Securities | Buy |
Oct-28-20 | Initiated | UBS | Neutral |
Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Oct-12-20 | Upgrade | Truist | Hold → Buy |
Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
Oct-09-20 | Downgrade | Truist | Buy → Hold |
Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Apr-15-20 | Resumed | Guggenheim | Neutral |
Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Feb-27-20 | Initiated | Barclays | Equal Weight |
Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-24-19 | Initiated | Raymond James | Mkt Perform |
Dec-17-19 | Resumed | Morgan Stanley | Overweight |
Nov-12-19 | Initiated | SunTrust | Buy |
Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Oct-17-19 | Resumed | BofA/Merrill | Neutral |
Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
AMGEN Inc. Stock (AMGN) Latest News
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks Investment Research
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Benzinga
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Zacks Investment Research
Better Buy: Pfizer vs. Viking Therapeutics
The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
The Motley Fool
AMGEN Inc. Stock (AMGN) Financials Data
AMGEN Inc. (AMGN) Revenue 2024
AMGN reported a revenue (TTM) of $28.19 billion for the quarter ending December 31, 2023, a +7.09% rise year-over-year.
AMGEN Inc. (AMGN) Net Income 2024
AMGN net income (TTM) was $6.72 billion for the quarter ending December 31, 2023, a +2.52% increase year-over-year.
AMGEN Inc. (AMGN) Cash Flow 2024
AMGN recorded a free cash flow (TTM) of $7.36 billion for the quarter ending December 31, 2023, a -16.23% decrease year-over-year.
AMGEN Inc. (AMGN) Earnings per Share 2024
AMGN earnings per share (TTM) was $12.49 for the quarter ending December 31, 2023, a +3.14% growth year-over-year.
AMGEN Inc. Stock (AMGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Grygiel Nancy A. | SVP & CCO |
Dec 04 '23 |
Sale |
273.03 |
2,096 |
572,276 |
10,874 |
Graham Jonathan P | EVP, Gen. Counsel & Secy. |
Nov 08 '23 |
Sale |
272.81 |
10,000 |
2,728,136 |
28,078 |
AMGEN INC | 10% Owner |
Sep 19 '23 |
Buy |
17.00 |
1,764,705 |
29,999,985 |
35,368,653 |
Gordon Murdo | EVP, Global Commercial Ops |
Aug 10 '23 |
Sale |
262.43 |
9,558 |
2,508,306 |
44,308 |
About AMGEN Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Cap:
|
Volume (24h):